Yara Abdou, MD, MSCR (@YAbdouMD) ranks #11 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 24 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: OPTIMA (UK), RXPONDER, HER2CLIMB-05. CMS Open Payments lists $10,880 in 2025 general payments.
At a Glance
- 6 posts naming a trial in 2026
- 5 trials discussed by name
- Breast Cancer: US #11, Global #21 · 24 physicians engaged
- CMS Open Payments lists $10,880 in 2025 general payments.
This Month
What Yara Abdou, MD, MSCR has posted in the last 30 days. Updated November 10, 2026.
Check out our new publication: “From TAILORx to OPTIMA, genomic assays continue to reshape chemotherapy decisions in HR+/HER2− breast cancer” @JCO_ASCO @DrLisaCarey @UNC_Lineberger https://t.co/O0JeyLVLRI Thanks for sharing our paper @DrRishabhOnco https://t.co/Md3CRgbh9j
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Yara Abdou, MD, MSCR
Physicians who reposted Yara Abdou, MD, MSCR’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #11 | #21 | 24 | 30 | Full ranking |
What Colleagues Are Saying About Yara Abdou, MD, MSCR
2026 posts by fellow physicians that mention @YAbdouMD, quoted word for word.
🚨 Are we overtreating early breast cancer with chemotherapy? A timely perspective in @JCO_ASCO revisits 4 landmark trials: MINDACT → TAILORx → RxPONDER → OPTIMA. The evolution of genomic-guided chemotherapy in HR+/HER2− breast cancer is fascinating. 🔹 MINDACT | MammaPrint High clinical risk ≠ automatic chemotherapy. Favorable genomic biology can support omission. 🔹 TAILORx | Oncotype DX Most node-negative patients with RS 11–25 can avoid chemotherapy. Younger women remain an important exception. 🔹 RxPONDER | Oncotype DX With 1–3 positive nodes and RS ≤25: • Postmenopausal: No meaningful chemotherapy benefit. • Premenopausal: Significant benefit persists. 🔹 OPTIMA | Prosigna (PAM50) The next frontier! ✅ Included patients with up to 9 positive nodes. ✅ ROR ≤60 guided chemotherapy omission. ✅ ~2/3 avoided chemotherapy. ✅ Genomic-guided treatment was noninferior at 3.9 years’ median follow-up. But here’s the BIG unanswered question: Does chemotherapy benefit younger women because of its cytotoxic effects, or because it suppresses ovarian function? OPTIMA mandated ovarian suppression in premenopausal participants and found no significant heterogeneity by menopausal status. This is hypothesis-generating, NOT definitive proof. 🔬 Next to watch: OFSET (NRG-BR009) and OPTIMA-YOUNG. 💡 My takeaway: The future isn’t simply identifying who can skip chemotherapy. It’s determining whether optimized endocrine therapy can replace chemotherapy in selected younger women. Excellent perspective by @YAbdouMD and Lisa Carey. @myesmo @ESMO_open @OncoAlert #BreastCancer #PrecisionOncology #ESMO26 Full paper link in comment below ⬇️
Trials Yara Abdou, MD, MSCR Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| OPTIMA (UK) | 2 | #6 of 24 | Nov 2, 2026 |
| RXPONDER | 1 | — | Oct 8, 2026 |
| HER2CLIMB-05 | 1 | #5 of 19 | Jun 2, 2026 |
| EVERA | 1 | #13 of 30 | May 31, 2026 |
| ASCENT-04 | 1 | #21 of 24 | May 31, 2026 |
Yara Abdou, MD, MSCR on OPTIMA (UK)
Check out our new publication: “From TAILORx to OPTIMA, genomic assays continue to reshape chemotherapy decisions in HR+/HER2− breast cancer” @JCO_ASCO @DrLisaCarey @UNC_Lineberger https://t.co/O0JeyLVLRI Thanks for sharing our paper @DrRishabhOnco https://t.co/Md3CRgbh9j
OPTIMA at #ASCO26 met non-inferiority, suggesting many patients with high-risk HR+/HER2- early breast cancer — including premenopausal patients with node-positive disease and low ROR scores — did not derive meaningful benefit from chemotherapy. Important step toward biologically https://t.co/HrLuLWAXtJ
Yara Abdou, MD, MSCR on RXPONDER
Same Recurrence Score. Different underlying biology. Our recent #RxPONDER analysis in @JNCI_Now found that gene pathway components (proliferation, ER, HER2) differed by race/ethnicity despite similar overall recurrence scores. Could looking inside the score help us understand outcome disparities? @KalinskyKevin @UNC_Lineberger @WinshipAtEmory @SWOG https://t.co/vPFHhqnRoQ https://t.co/9cP9TPM1WL
Yara Abdou, MD, MSCR on HER2CLIMB-05
HER2CLIMB05: The PFS benefit with tucatinib + HP maintenance was consistent across de novo/recurrent disease, HR+ and HR− tumors, and patients with or without brain metastases. Notably, among patients with baseline brain metastases, median PFS doubled from 4.2 to 8.5 months https://t.co/bDWiKaNagD
Yara Abdou, MD, MSCR on EVERA
evERA: Giredestrant + everolimus showed favorable interim OS trends, prolonged PFS2, and extended chemotherapy-free survival — particularly in the ESR1m population. Another step toward delaying chemotherapy while improving outcomes. @jhaveri_komal 👏🏼 #ASCO26 #bcsm @OncoAlert https://t.co/Dj2ojjzqMG
Yara Abdou, MD, MSCR on ASCENT-04
#ASCENT04: PFS benefit with SG + pembro consistent across biomarker subgroups — including TROP2 expression quartiles, BRCA status, and HER2 status. Biomarkers that truly refine patient selection beyond broad subgroup labels continues to be needed. @stolaney1 👏🏼 #ASCO26 #bcsm https://t.co/STzU6AtLeR
Yara Abdou, MD, MSCR’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Martine Piccart has crowned giredestrant the new queen 👑 of adjuvant ET! And the 👑 rules across menopausal status: At #ASCO26, adjuvant giredestrant demonstrated consistent IDFS and DRFI benefit in both pre- and post-menopausal HR+ early breast cancer, with fewer discontinuations due to musculoskeletal pain compared with SOC ET. #bcsm @OncoAlert
Super excited for #ASCO26 🙌 Completely agree—one of the best parts of @ASCO is seeing friends and colleagues from around the globe. Can’t wait to catch up and of course see the superstar @OncBrothers 🤩 https://t.co/lJ4T7P9fm2
Lots of exciting data coming at #ASCO26 🤩 Looking forward to all the discussions ahead! #bcsm @ASCO @OncLive @UNC_Lineberger https://t.co/PWaks5SfKs
The spectacular ASCO Editorial Board team at #ASCO2026 Great to meet/see some amazing colleagues @montypal @neerajaiims @MeganKruseMD @ryangentzler @Dr_JeannyAC #bcsm @ASCO https://t.co/XWOdMhsfuR
In 2026, the real question in locoregional management is no longer whether we can avoid ALND — it’s identifying the patients where ALND still truly matters.. #ASCO26 #bcsm @OncoAlert @DrJudyBoughey https://t.co/cdEaQWwQKY
Industry Payments
CMS Open Payments · 2025 general payments
$10,880 across 4 payments